{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "The reported effects are based on preclinical models and retrospective human data, not from a prospective randomized trial."
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing and presentation pathways increase after vaccination.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
          "line_ref": "L29"
        }
      ],
      "caveat": "The measurements of antigen presentation were from mouse models and may not fully represent human tumor biology."
    },
    {
      "claim_id": "C03",
      "claim": "The mRNA vaccination improves tumor visibility to T cells and increases immune infiltration.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x",
          "line_ref": "L33"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "The observed increase in T-cell density is a valuable indicator, but does not solely prove a direct causal link to improved tumor destruction in humans."
    },
    {
      "claim_id": "C04",
      "claim": "Prior mRNA vaccination is associated with improved survival in patients receiving ICI treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A",
          "line_ref": "L30"
        },
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    }
  ]
}
